Healthcare provider profile · identity verified

Matthew Yang

Internal Medicine · HOUSTON, TX · NPI 1215432505

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	254	92
Amlodipine Besylate	Amlodipine Besylate	149	66
Gabapentin	Gabapentin	147	40
Rosuvastatin Calcium	Rosuvastatin Calcium	143	58
Levothyroxine Sodium	Levothyroxine Sodium	139	50
Fluticasone Propionate	Fluticasone Propionate	127	54
Ozempic	Semaglutide	112	31
Omeprazole	Omeprazole	93	37
Lisinopril	Lisinopril	74	25
Losartan Potassium	Losartan Potassium	73	31
Metformin Hcl Er	Metformin Hcl	73	30
Carvedilol	Carvedilol	71	31
Albuterol Sulfate Hfa	Albuterol Sulfate	67	32
Allopurinol	Allopurinol	65	20
Tramadol Hcl	Tramadol Hcl	63	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	62	26
Famotidine	Famotidine	58	27
Mounjaro	Tirzepatide	57	suppressed
Furosemide	Furosemide	56	23
Montelukast Sodium	Montelukast Sodium	55	18
Nifedipine Er	Nifedipine	54	20
Hydroxyzine Hcl	Hydroxyzine Hcl	51	20
Metformin Hcl	Metformin Hcl	50	22
Simvastatin	Simvastatin	42	17
Hydrochlorothiazide	Hydrochlorothiazide	41	18
Jardiance	Empagliflozin	38	13
Pantoprazole Sodium	Pantoprazole Sodium	37	17
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	31	13
Clopidogrel	Clopidogrel Bisulfate	29	13
Escitalopram Oxalate	Escitalopram Oxalate	28	11
Metoprolol Succinate	Metoprolol Succinate	28	15
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	28	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	suppressed
Mirtazapine	Mirtazapine	27	suppressed
Azelastine Hcl	Azelastine Hcl	26	15
Duloxetine Hcl	Duloxetine Hcl	26	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	11
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Trazodone Hcl	Trazodone Hcl	22	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Ibuprofen	Ibuprofen	21	suppressed
Valsartan	Valsartan	21	suppressed
Finasteride	Finasteride	20	suppressed
Meloxicam	Meloxicam	20	suppressed
Sertraline Hcl	Sertraline Hcl	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Ezetimibe	Ezetimibe	18	11
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Ondansetron Odt	Ondansetron	17	12
Sod Sulf-Potass Sulf-Mag Sulf	Sodium, Potassium,mag Sulfates	17	17
Tolterodine Tartrate Er	Tolterodine Tartrate	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	14
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Rybelsus	Semaglutide	16	suppressed
Valacyclovir	Valacyclovir Hcl	16	suppressed
Atenolol	Atenolol	15	suppressed
Eliquis	Apixaban	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Alendronate Sodium	Alendronate Sodium	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Nystatin	Nystatin	14	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	14	suppressed
Azithromycin	Azithromycin	13	13
Dexlansoprazole Dr	Dexlansoprazole	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Nystop	Nystatin	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error